Outcomes of Hormone receptor-positive/HER2-negative early breast cancer patients by risk of recurrence groups focusing on the intermediate-risk group: Retrospective analysis from GEICAM studies

Abstract Purpose Endocrine therapy (ET) with or without abemaciclib/ribociclib is the current standard for intermediate- and high-risk hormone receptor (HR)-positive/HER2-negative early breast cancer (EBC) patients. The NATALEE trial showed that adding 3 years of ribociclib to ET improves the 4-year...

Descrición completa

Detalles Bibliográficos

Principais autores:	Sonia Servitja, Eva Carrasco, Raquel Andrés, Álvaro Rodríguez-Lescure, Miguel Martín, Manuel Ruiz-Borrego, Ángel Guerrero, Begoña Bermejo, Antonio Antón, Montserrat Muñoz, Mireia Margeli, Isabel Álvarez, Luis Antonio Fernández, Jose Ponce, Josefina Cruz, Purificación Martínez, Sara López-Tarruella, Margarita Amenedo, Andrea Blasco, Óscar Polonio, Miguel Gil-Gil
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMC 2026-05-01
Series:	Breast Cancer Research
Assuntos:	Early breast cancer Hormone receptor (HR)-positive/HER2-negative Risk of recurrence cohorts
Acceso en liña:	https://doi.org/10.1186/s13058-026-02300-0
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!